Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

2.980 -0.120 (-3.87%)
Streaming Delayed Price Updated: 3:23 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 174,989
Open 3.170
Bid (Size) 2.970 (4)
Ask (Size) 3.000 (1)
Prev. Close 3.100
Today's Range 2.970 - 3.179
52wk Range 2.450 - 5.936
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
Via Investor Brand Network
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace

Performance

YTD
-42.14%
-42.14%
1 Month
-14.12%
-14.12%
3 Month
-9.97%
-9.97%
6 Month
-28.19%
-28.19%
1 Year
-47.54%
-47.54%

More News

Read More
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call
Via Investor Brand Network
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
From Vistagen
Via Business Wire
3 Stocks Under $15 That Could Make You a Millionaire
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor
Via Investor Brand Network
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
From Vistagen
Via Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update
Via Investor Brand Network
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call
Via Investor Brand Network
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
From Vistagen
Via Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference
Via Investor Brand Network
Vistagen to Present at the Jefferies Global Healthcare Conference
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference
Via Investor Brand Network
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
From Vistagen
Via Business Wire
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
Via InvestorPlace
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference
Via Investor Brand Network
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement
Via Investor Brand Network
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
From Vistagen
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.